Market cap
$1.35B
Shares out
59.6M

Windward Bio Group AG (WWB) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 14 wire items for WWB, including 12 insider trades, 1 SEC filing and 1 press release or news item. The most recent was published Nov 18, 2026.

Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target binding or effector function silencing. We believe our product candidates have the potential to deliver better clinical outcomes while offering the convenience of less frequent dosing than currently available treatments.

News · 26 weeks14+100%
2026-05-24: 02026-05-31: 02026-06-07: 02026-06-14: 02026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 02026-08-02: 02026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 02026-11-08: 02026-11-15: 14
2026-05-242026-11-15
Mix1490d
  • Insider12(86%)
  • SEC Filings1(7%)
  • Other1(7%)
Activity · 52 weeks143 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

14 items

WWB FAQ

7 questions
  • What does Windward Bio Group AG do?
    Windward Bio Group is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis. Our product candidates, WIN378 and WIN027, target clinically validated disease pathways and are engineered to remain in the body for extended periods of time, enabling less frequent dosing than currently available treatments. This design feature is combined with additional properties including enhanced target affinity, dual target...
  • What is the latest news on WWB?
    In the last 30 days Quantisnow tracked 14 wire items for WWB: 12 insider trades, 1 SEC filing and 1 press release or news item. The most recent was published on November 18, 2026.
  • Where does WWB stock trade?
    Windward Bio Group AG (WWB) is listed on NASDAQ.
  • What sector and industry is WWB in?
    Windward Bio Group AG operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did Windward Bio Group AG go public?
    Windward Bio Group AG (WWB) completed its IPO in 2026.
  • What companies are similar to WWB?
    Notable peers in the same industry include BIIB (Biogen Inc.), MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.), RVMD (Revolution Medicines Inc.), AMGN (Amgen Inc.). Compare WWB side-by-side with any of them on Quantisnow.
  • How can I track WWB on Quantisnow?
    Quantisnow aggregates Windward Bio Group AG's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WWB to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change